MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/22143602261485046

Медицинская библиотека · Journal of neuromuscular diseases · 2026

Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions.

Weber David R, Ahmet Alexandra, Kinnett Kathi, Lautatzis Maria-Elena, McMillan Hugh J, Apkon Susan, Bansal Shipra, Benjamin Robert W, Clemens Paula R, Crane Janet L, Fiscaletti Melissa, Lam Carol, McAdam Laura, Rutter Meilan M, Merchant Nadia, Nasomyont Nat, Nicolau Stefan, Phung Kim, Renthal Nora, Scavina Mena, Sorbara Julia, Tamaroff Jaclyn, Tian Cuixia, Wood Claire, Aversa Tommaso, Bello Luca, Corbetta Sabrina, Cumbo Francesca, De Sanctis Luisa, Di Iorgi Natascia, Ferlin Alberto, Fintini Danilo, Mercuri Eugenio Maria, Panicucci Chiara, Tornese Gianluca, Schrader Rachel, Selby Kathryn A, Veerapandiyan Aravindhan, Wong Sze Choong, Ward Leanne M, Sbrocchi Anne Marie

СтатьяОбзорПеревод в очереди

Аннотация

Duchenne muscular dystrophy (DMD) is an X-linked recessive dystrophinopathy characterized by progressive loss of muscle strength, respiratory insufficiency, cardiac dysfunction, and premature death. Despite a rapidly evolving therapeutic landscape that now includes multiple disease modifying treatments including exon skipping medications, microdystrophin gene therapy, and givinostat, high dose glucocorticoids (GCs) initiated at a young age remain central to the standard of care for DMD. Individuals treated with GCs are at high risk of adrenal insufficiency, an iatrogenic and potentially life-threatening condition that can arise from adrenal suppression caused by prolonged exposure to supraphysiologic doses of GCs. The objective of this manuscript is to provide an up-to-date review of the best practices for the management of adrenal insufficiency in individuals with DMD treated with GCs. The approach described in this document also applies to individuals with related dystrophinopathies including Becker muscular dystrophy and female manifesting carriers treated with GCs, recognizing that GCs are not standard of care for these conditions and are prescribed on an individualized basis at some centers to severely affected individuals. Key themes discussed include best practices for individual and caregiver education about adrenal suppression, creation and implementation of stress steroid plans, safe transition between GC treatment regimens, and discontinuation of GC therapy.

Для цитирования: Weber David R, Ahmet Alexandra, Kinnett Kathi, Lautatzis Maria-Elena, McMillan Hugh J, Apkon Susan, Bansal Shipra, Benjamin Robert W, Clemens Paula R, Crane Janet L, Fiscaletti Melissa, Lam Carol, McAdam Laura, Rutter Meilan M, Merchant Nadia, Nasomyont Nat, Nicolau Stefan, Phung Kim, Renthal Nora, Scavina Mena, Sorbara Julia, Tamaroff Jaclyn, Tian Cuixia, Wood Claire, Aversa Tommaso, Bello Luca, Corbetta Sabrina, Cumbo Francesca, De Sanctis Luisa, Di Iorgi Natascia, Ferlin Alberto, Fintini Danilo, Mercuri Eugenio Maria, Panicucci Chiara, Tornese Gianluca, Schrader Rachel, Selby Kathryn A, Veerapandiyan Aravindhan, Wong Sze Choong, Ward Leanne M, Sbrocchi Anne Marie. Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions.. Journal of neuromuscular diseases. 2026. DOI: 10.1177/22143602261485046.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.